Q-omics provides the consensus-scored ZNF705G profile across patient tissues and cancer cell-line models. ZNF705G expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, ZNF705G is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, ZNF705G RNA expression shows 6,446 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight SKCM, BRCA, and STAD as cancer lineages where ZNF705G shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF705G — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF705G survival associations across molecular data types. ZNF705G RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF705G RNA expression–survival associations across cancer types. High ZNF705G expression shows unfavorable associations in SKCM, UVM, SARC, KICH, THCA and GBM. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for ZNF705G RNA expression.
This table summarizes ZNF705G tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF705G. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF705G shows lower tumor expression in BRCA, LUSC and THCA and higher tumor expression in KIRC and HNSC. The BRCA box plot shows higher ZNF705G RNA expression in normal versus tumor tissue (log2 FC = −0.007, t-test p < 0.001).
This table shows molecular features associated with ZNF705G in patient tissues and cancer cell lines. In patient samples, ZNF705G shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF705G RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
